An update review of new therapies in sickle cell disease: the prospects for drug combinations

References

• Piel FB, Steinberg MH, Rees DC, et al. Sickle cell disease. N Engl J Med. 2017;376(16):1561–1573. doi: 10.1056/NEJMra1510865
   PubMed Web of Science ®Google Scholar
• Esham KS, Rodday AM, Smith HP, et al. Assessment of health-related quality of life among adults hospitalized with sickle cell disease vaso-occlusive crisis. Blood Adv. 2020;4(1):19–27. doi: 10.1182/bloodadvances.2019000128
   PubMed Web of Science ®Google Scholar
• Piel FB, Rees DC, DeBaun MR, et al. Defining global strategies to improve outcomes in sickle cell disease: a lancet haematology commission. Lancet Haematol. 2023;10(8):e633–e686. doi: 10.1016/S2352-3026(23)00096-0
   PubMed Web of Science ®Google Scholar
• Chou ST, Alsawas M, Fasano RM, et al. American society of hematology 2020 guidelines for sickle cell disease: transfusion support. Blood Adv. 2020;4(2):327–355. doi: 10.1182/bloodadvances.2019001143
   PubMed Web of Science ®Google Scholar
• Ataga KI. The challenge of clinical end points in sickle cell disease. Blood. 2023;142(24):2047–2054. doi: 10.1182/blood.2023021220
   PubMed Web of Science ®Google Scholar
• Ali MA, Ahmad A, Chaudry H, et al. Efficacy and safety of recently approved drugs for sickle cell disease: a review of clinical trials. Exp Hematol. 2020;92:11–18. doi: 10.1016/j.exphem.2020.08.008
   PubMed Web of Science ®Google Scholar
• Salinas Cisneros G, Thein SL. Research in sickle cell disease: from bedside to bench to bedside. Hemasphere. 2021;5(6):e584. doi: 10.1097/HS9.0000000000000584
   PubMed Web of Science ®Google Scholar
• Tshilolo L, Tomlinson G, Williams TN, et al. Hydroxyurea for children with sickle cell anemia in Sub-Saharan Africa. N Engl J Med. 2019;380(2):121–131. doi: 10.1056/NEJMoa1813598
   PubMed Web of Science ®Google Scholar
• Opoka RO, Ndugwa CM, Latham TS, et al. Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia. Blood. 2017;130(24):2585–2593. doi: 10.1182/blood-2017-06-788935
   PubMed Web of Science ®Google Scholar
• John CC, Opoka RO, Latham TS, et al. Hydroxyurea Dose Escalation for Sickle Cell Anemia in Sub-Saharan Africa. N Engl J Med. 2020;382(26):2524–2533. doi: 10.1056/NEJMoa2000146
   PubMed Web of Science ®Google Scholar
• Alvarez O, Yovetich NA, Scott JP, et al. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol. 2013;88(11):932–938. doi: 10.1002/ajh.23547
   PubMed Web of Science ®Google Scholar
• Ware R, Schultz W, Yovetich N, et al. Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer. 2011;57(6):1011–1017. doi: 10.1002/pbc.23145
   PubMed Web of Science ®Google Scholar
• Ware RE, Helms RW. SWITCH investigators. Stroke with transfusions changing to hydroxyurea (SWiTCH). Blood. 2012;119(17):3925–3932. doi: 10.1182/blood-2011-11-392340
   PubMed Web of Science ®Google Scholar
• Ware RE, Davis BR, Schultz WH, et al. Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial. Lancet. 2016;387(10019):661–670. doi: 10.1016/S0140-6736(15)01041-7
   PubMed Web of Science ®Google Scholar
• Galadanci NA, Umar Abdullahi S, Vance LD, et al. Feasibility trial for primary stroke prevention in children with sickle cell anemia in Nigeria (SPIN trial). Am J Hematol. 2017;92(8):780–788. doi: 10.1002/ajh.24770
   PubMed Web of Science ®Google Scholar
• Galadanci NA, Abdullahi SU, Ali Abubakar S, et al. Moderate fixed-dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: final results of the SPIN trial. Am J Hematol. 2020;95(9):E247–E250. doi: 10.1002/ajh.25900
   PubMed Web of Science ®Google Scholar
• Abdullahi SU, Jibir BW, Bello-Manga H, et al. Hydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial. Lancet Haematol. 2022;9(1):e26–e37. doi: 10.1016/S2352-3026(21)00368-9
   PubMed Web of Science ®Google Scholar
• Ambrose EE, Latham TS, Songoro P, et al. Hydroxyurea with dose escalation for primary stroke risk reduction in children with sickle cell anaemia in Tanzania (SPHERE): an open-label, phase 2 trial. Lancet Haematol. 2023;10(4):e261–e271. doi: 10.1016/S2352-3026(22)00405-7
   PubMed Web of Science ®Google Scholar
• Hankins JS, Mccarville MB, Rankine-Mullings A, et al. Prevention of conversion to abnormal transcranial doppler with hydroxyurea in sickle cell anemia: a phase III international randomized clinical trial. Am J Hematol. 2015;90(12):1099–1105. doi: 10.1002/ajh.24198
   PubMed Web of Science ®Google Scholar
• Nieves RM, Latham T, Marte N, et al. Hydroxyurea with dose escalation to reduce primary stroke risk in children with sickle cell anemia in Dominican Republic: the sacred trial. Blood. 2022;140(Supplement 1):451–452. doi: 10.1182/blood-2022-168324
   PubMedGoogle Scholar
• Rankine-Mullings A, Reid M, Soares D, et al. Hydroxycarbamide treatment reduces transcranial doppler velocity in the absence of transfusion support in children with sickle cell anaemia, elevated transcranial doppler velocity, and cerebral vasculopathy: the EXTEND trial. Br J Haematol. 2021;195(4):612–620. doi: 10.1111/bjh.17698
   PubMed Web of Science ®Google Scholar
• Molokie R, Lavelle D, Gowhari M, et al. Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study. PLoS Med. 2017;14(9):e1002382. doi: 10.1371/journal.pmed.1002382
   PubMed Web of Science ®Google Scholar
• Andemariam B, Højlund Nielsen P, Zillmer R, et al. ASCENT1: a phase 2 trial to evaluate the efficacy and safety of oral decitabine-tetrahydrouridine (NDec) in patients with sickle cell disease. Blood. 2022;140(Supplement 1):5420–5421. doi: 10.1182/blood-2022-169283
   Google Scholar
• Cao H, Stamatoyannopoulos G, Jung M. Induction of human γ globin gene expression by histone deacetylase inhibitors. Blood. 2004;103(2):701–709. doi: 10.1182/blood-2003-02-0478
   PubMed Web of Science ®Google Scholar
• McCaffrey PG, Newsome DA, Fibach E, et al. Induction of γ-globin by histone deacetylase inhibitors. Blood. 1997;90(5):2075–2083. doi: 10.1182/blood.V90.5.2075
   PubMed Web of Science ®Google Scholar
• Perrine S, Ginder G, Faller D, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med. 1993;328(2):81–86. doi: 10.1056/NEJM199301143280202
   PubMed Web of Science ®Google Scholar
• Selby R, Nisbet-Brown E, Basran R, et al. Valproic acid and augmentation of fetal hemoglobin in individuals with and without sickle cell disease. Blood. 1997;90(2):891–893. doi: 10.1182/blood.V90.2.891
   PubMed Web of Science ®Google Scholar
• Kutlar A, Reid ME, Inati A, et al. A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. Am J Hematol. 2013;88(11):E255–E260. doi: 10.1002/ajh.23533
   PubMed Web of Science ®Google Scholar
• Okam M, Esrick E, Mandell E, et al. Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. Blood. 2015;125(23):3668–3669. doi: 10.1182/blood-2015-03-635391
   PubMed Web of Science ®Google Scholar
• Study details | study of panobinostat (LBH589) in patients with sickle cell disease | ClinicalTrials.Gov [Internet]. [cited 2023 Dec 4]. Available from: https://clinicaltrials.gov/study/NCT01245179
   Google Scholar
• McArthur JG, Svenstrup N, Chen C, et al. A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease. Haematologica. 2020;105(3):623–631. doi: 10.3324/haematol.2018.213462
   PubMed Web of Science ®Google Scholar
• Andemariam B, Bronte L, Gordeuk V, et al. The safety, pharmacokinetics & pharmacodynamic effects of IMR-687, a highly-selective PDE9 inhibitor, in adults with sickle cell disease: phase-2A placebo-controlled & open-label extension studies. Hemasphere. 2021;5:90.
   Google Scholar
• Oder E, Safo MK, Abdulmalik O, et al. New developments in anti-sickling agents: can drugs directly prevent the polymerization of sickle haemoglobin in vivo? Br J Haematol Med. 2016;175:24–30.
   PubMed Web of Science ®Google Scholar
• Hutchaleelaha A, Patel M, Washington C, et al. Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease. Br J Clin Pharmacol. 2019;85(6):1290–1302. doi: 10.1111/bcp.13896
   PubMed Web of Science ®Google Scholar
• Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized trial of voxelotor in sickle cell disease. N Engl J Med. 2019;381(6):509–519. doi: 10.1056/NEJMoa1903212
   PubMed Web of Science ®Google Scholar
• Howard J, Ataga K, Brown R, et al. Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2021;8(5):e323–e333. doi: 10.1016/S2352-3026(21)00059-4
   PubMedGoogle Scholar
• Estepp JH, Kalpatthi R, Woods G, et al. Safety and efficacy of voxelotor in pediatric patients with sickle cell disease aged 4 to 11 years. Pediatr Blood Cancer. 2022;69(8):e29716. doi: 10.1002/pbc.29716
   PubMed Web of Science ®Google Scholar
• Saraf SL, Abdullahi SU, Akinsete AM, et al. Preliminary results from a multicenter phase 2/3 study of next-generation HbS polymerization inhibitor GBT021601 for the treatment of patients with sickle cell disease. Blood. 2023;142(Supplement 1):274. doi: 10.1182/blood-2023-177781
   PubMedGoogle Scholar
• Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429–439. doi: 10.1056/NEJMoa1611770
   PubMed Web of Science ®Google Scholar
• Liles DK, Shah NR, Scullin B, et al. Long-term biological effects in sickle cell disease: insights from a post-crizanlizumab study. Br J Haematol. 2021;195(4):e150–e153. doi: 10.1111/bjh.17739
   PubMed Web of Science ®Google Scholar
• Kutlar A, Kanter J, Liles DK, et al. Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis. Am J Hematol. 2019;94(1):55–61. doi: 10.1002/ajh.25308
   PubMed Web of Science ®Google Scholar
• Telen MJ, Wun T, McCavit TL, et al. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015;125(17):2656–2664. doi: 10.1182/blood-2014-06-583351
   PubMed Web of Science ®Google Scholar
• Dampier CD, Telen MJ, Wun T, et al. A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis. Blood. 2023;141(2):168–179. doi: 10.1182/blood.2022015797
   PubMed Web of Science ®Google Scholar
• Biemond B, Tombak A, Kilinc Y, et al. Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Haematol. 2021;8(5):e334–e343. doi: 10.1016/S2352-3026(21)00053-3
   PubMed Web of Science ®Google Scholar
• Dansdill D, Halandras PM, Beverly J, et al. Synthetic, organic compound vepoloxamer (P-188) potentiates tissue plasminogen activator. J Vasc Surg. 2018;67(1):294–299. doi: 10.1016/j.jvs.2016.03.473
   PubMed Web of Science ®Google Scholar
• Adams-Graves P, Kedar A, Koshy M, et al. RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study. Blood. 1997;90(5):2041–2046. doi: 10.1182/blood.V90.5.2041
   PubMed Web of Science ®Google Scholar
• Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 2001;286(17):2099–2106. doi: 10.1001/jama.286.17.2099
   PubMed Web of Science ®Google Scholar
• Casella J, Barton B, Kanter J, et al. Effect of poloxamer 188 vs placebo on painful vaso-occlusive episodes in children and adults with sickle cell disease: a randomized clinical trial. JAMA. 2021;325(15):1513–1523. doi: 10.1001/jama.2021.3414
   PubMed Web of Science ®Google Scholar
• Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l -glutamine in sickle cell disease. N Engl J Med. 2018;379(3):226–235. doi: 10.1056/NEJMoa1715971
   PubMed Web of Science ®Google Scholar
• Zaidi AU, Estepp J, Shah N, et al. A reanalysis of pain crises data from the pivotal L-glutamine in sickle cell disease trial. Contemp Clin Trials. 2021;110:106546. doi: 10.1016/j.cct.2021.106546
   PubMed Web of Science ®Google Scholar
• Morris SM, Jr. Recent advances in arginine metabolism: roles and regulation of the arginases. Br J Pharmacol. 2000;157(6) :922–930. doi: 10.1111/j.1476-5381.2009.00278.x
   Google Scholar
• Morris CR, Kuypers FA, Lavrisha L, et al. A randomized, placebo-controlled trial of arginine therapy for the treatment of children with sickle cell disease hospitalized with vaso-occlusive pain episodes. Haematologica. 2013;98(9):1375–1382. doi: 10.3324/haematol.2013.086637
   PubMed Web of Science ®Google Scholar
• Morris CR, Brown LAS, Reynolds M, et al. Impact of arginine therapy on mitochondrial function in children with sickle cell disease during vaso-occlusive pain. Blood. 2020;136(12):1402–1406. doi: 10.1182/blood.2019003672
   PubMed Web of Science ®Google Scholar
• Onalo R, Cooper P, Cilliers A, et al. Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria. Am J Hematol. 2021;96(1):89–97. doi: 10.1002/ajh.26028
   PubMed Web of Science ®Google Scholar
• Dumas G, Habibi A, Onimus T, et al. Eculizumab salvage therapy for delayed hemolysis transfusion reaction in sickle cell disease patients. Blood. 2016;127(8):1062–1064. doi: 10.1182/blood-2015-09-669770
   PubMed Web of Science ®Google Scholar
• McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734–737. doi: 10.15585/mmwr.mm6627e1
   PubMed Web of Science ®Google Scholar
• Chonat S, Graciaa S, Shin HS, et al. Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease. Haematologica. 2020;105(12):2887–2891. doi: 10.3324/haematol.2020.262006
   PubMed Web of Science ®Google Scholar
• Azul M, Shah S, Williams S, et al. Evidence for complement-mediated bone marrow necrosis in a young adult with sickle cell disease. Blood Cells Mol Dis United States. 2021;86:102508. doi: 10.1016/j.bcmd.2020.102508
   PubMed Web of Science ®Google Scholar
• Callaghan M, Ataga K, De Franceschi L, et al. P120: trial in progress: the randomized, double-blind, placebo-controlled phase 2A crosswalk-c trial evaluating the efficacy of crovalimab as adjunct treatment in the prevention of Vaso-Occlusive Episodes (VOES) in Patients (PTS) with Sickle Cell Disease (SCD). Hemasphere. 2022;6:27–28. doi: 10.1097/01.HS9.0000821572.78026.e4
   Google Scholar
• Xu JZ, Conrey A, Frey I, et al. A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease. Blood. 2022;140(19):2053–2062. doi: 10.1182/blood.2022015403
   PubMed Web of Science ®Google Scholar
• van Dijk MJ, Rab MAE, van Oirschot BA, et al. Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: a phase 2, open-label study. Am J Hematol. 2022;97(7):E226–E229. doi: 10.1002/ajh.26554
   PubMed Web of Science ®Google Scholar
• Study details | a study evaluating the efficacy and safety of mitapivat (AG-348) in participants with sickle cell disease (RISE UP) | ClinicalTrials.Gov [Internet]. [cited 2023 Dec 10]. Available from: https://clinicaltrials.gov/study/NCT05031780
   Google Scholar
• Forsyth S, Schroeder P, Geib J, et al. Safety, pharmacokinetics, and pharmacodynamics of etavopivat (FT-4202), an allosteric activator of pyruvate kinase-R, in healthy adults: a randomized, placebo-controlled, double-blind, first-in-human phase 1 trial. Clin Pharmacol Drug Dev. 2022;11(5):654–665. doi: 10.1002/cpdd.1058
   PubMed Web of Science ®Google Scholar
• Study details | a study of Etavopivat in adults and adolescents with sickle cell disease (HIBISCUS) | ClinicalTrials.Gov [Internet]. [cited 2023 Dec 10]. Available from: https://www.clinicaltrials.gov/study/NCT04624659
   Google Scholar
• Iqbal M, Reljic T, Corbacioglu S, et al. Systematic review/Meta-analysis on efficacy of allogeneic hematopoietic cell transplantation in sickle cell disease: an international effort on behalf of the pediatric diseases working party of European society for blood and marrow transplantation and th. Transplant Cell Ther. 2021;27(2):.e167.1–.e167.12. doi: 10.1016/j.jtct.2020.10.007
   Google Scholar
• Bhatia M, Kolva E, Cimini L, et al. Health-related quality of life after allogeneic hematopoietic stem cell transplantation for sickle cell disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2015;21(4):666–672. doi: 10.1016/j.bbmt.2014.12.007
   PubMed Web of Science ®Google Scholar
• Dedeken L, Lê PQ, Azzi N, et al. Haematopoietic stem cell transplantation for severe sickle cell disease in childhood: a single centre experience of 50 patients. Br J Haematol. 2014;165(3):402–408. doi: 10.1111/bjh.12737
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Kang EM, Fitzhugh CD, et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med. 2009;361(24):2309–2317. doi: 10.1056/NEJMoa0904971
   PubMed Web of Science ®Google Scholar
• Hulbert ML, Shenoy S. Hematopoietic stem cell transplantation for sickle cell disease: progress and challenges. Pediatr Blood Cancer. 2018;65(9):e27263. doi: 10.1002/pbc.27263
   PubMed Web of Science ®Google Scholar
• King AA, Kamani N, Bunin N, et al. Successful matched sibling donor marrow transplantation following reduced intensity conditioning in children with hemoglobinopathies. Am J Hematol. 2015;90(12):1093–1098. doi: 10.1002/ajh.24183
   PubMed Web of Science ®Google Scholar
• Locatelli F, Kabbara N, Ruggeri A, et al. Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling. Blood. 2013;122(6):1072–1078. doi: 10.1182/blood-2013-03-489112
   PubMed Web of Science ®Google Scholar
• Saraf SL, Oh AL, Patel PR, et al. Nonmyeloablative stem cell transplantation with Alemtuzumab/Low-dose irradiation to cure and improve the quality of life of adults with sickle cell disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2016;22(3):441–448. doi: 10.1016/j.bbmt.2015.08.036
   PubMed Web of Science ®Google Scholar
• Guilcher GMT, Truong TH, Saraf SL, et al. Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease. Semin Hematol. 2018;55(2):87–93. doi: 10.1053/j.seminhematol.2018.04.011
   PubMed Web of Science ®Google Scholar
• Abraham A, Hsieh M, Eapen M, et al. Relationship between mixed donor–recipient chimerism and disease recurrence after hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2017;23(12):2178–2183. doi: 10.1016/j.bbmt.2017.08.038
   PubMed Web of Science ®Google Scholar
• Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22(1):1–6. doi: 10.1038/sj.bmt.1701291
   PubMed Web of Science ®Google Scholar
• Bhatia M, Jin Z, Baker C, et al. Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease. Bone Marrow Transplant. 2014;49(7):913–920. doi: 10.1038/bmt.2014.84
   PubMed Web of Science ®Google Scholar
• Abraham A, Cluster A, Jacobsohn D, et al. Unrelated umbilical cord blood transplantation for sickle cell disease following reduced-intensity conditioning: results of a phase I trial. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2017;23(9):1587–1592. doi: 10.1016/j.bbmt.2017.05.027
   PubMed Web of Science ®Google Scholar
• Shenoy S, Eapen M, Panepinto JA, et al. A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. Blood. 2016;128(21):2561–2567. doi: 10.1182/blood-2016-05-715870
   PubMed Web of Science ®Google Scholar
• Foell J, Schulte JH, Pfirstinger B, et al. Haploidentical CD3 or α/β T-cell depleted HSCT in advanced stage sickle cell disease. Bone Marrow Transplant. 2019;54(11):1859–1867. doi: 10.1038/s41409-019-0550-0
   PubMed Web of Science ®Google Scholar
• Gaziev J, Isgrò A, Mozzi AF, et al. New insights into the pharmacokinetics of intravenous busulfan in children with sickle cell anemia undergoing bone marrow transplantation. Pediatr Blood Cancer. 2015;62(4):680–686. doi: 10.1002/pbc.25376
   PubMed Web of Science ®Google Scholar
• Limerick E, Abraham A. Across the myeloablative spectrum: hematopoietic cell transplant conditioning regimens for pediatric patients with sickle cell disease. J Clin Med. 2022;11(13):11. doi: 10.3390/jcm11133856
   Web of Science ®Google Scholar
• Vallée T, Schmid I, Gloning L, et al. Excellent outcome of stem cell transplantation for sickle cell disease. Ann Hematol. 2023;102(11):3217–3227. doi: 10.1007/s00277-023-05447-4
   PubMed Web of Science ®Google Scholar
• de la Fuente J, Dhedin N, Koyama T, et al. Haploidentical bone marrow transplantation with post-transplantation cyclophosphamide plus thiotepa improves donor engraftment in patients with sickle cell anemia: results of an international learning collaborative. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant. 2019;25(6):1197–1209. doi: 10.1016/j.bbmt.2018.11.027
   PubMed Web of Science ®Google Scholar
• Shenoy S. Umbilical cord blood: an evolving stem cell source for sickle cell disease transplants. Stem Cells Transl Med. 2013;2(5):337–340. doi: 10.5966/sctm.2012-0180
   PubMed Web of Science ®Google Scholar
• Bernaudin F, Dalle JH, Bories D, et al. Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France. Haematologica. 2020;105(1):91–101. doi: 10.3324/haematol.2018.213207
   PubMed Web of Science ®Google Scholar
• Thomson AM, McHugh TA, Oron AP. Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000–2021: a systematic analysis from the global burden of disease study 2021. Lancet Haematol. 2023;10(8):e585–e599. doi: 10.1016/S2352-3026(23)00118-7
   PubMed Web of Science ®Google Scholar
• Inam Z, Tisdale JF, Leonard A. Outcomes and long-term effects of hematopoietic stem cell transplant in sickle cell disease. Expert Rev Hematol. 2023;16(11):879–903. doi: 10.1080/17474086.2023.2268271
   PubMed Web of Science ®Google Scholar
• Lidonnici MR, Scaramuzza S, Ferrari G. Gene therapy for hemoglobinopathies. Hum Gene Ther. 2023;34(17–18):793–807. doi: 10.1089/hum.2023.138
   PubMed Web of Science ®Google Scholar
• Frangoul H, Locatelli F, Bhatia M, et al. Efficacy and safety of a single dose of exagamglogene autotemcel for severe sickle cell disease. Blood. 2022;140(Supplement 1):29–31. doi: 10.1182/blood-2022-162353
   Google Scholar
• Kanter J, Thompson AA, Pierciey FJJ, et al. Lovo-cel gene therapy for sickle cell disease: treatment process evolution and outcomes in the initial groups of the HGB-206 study. Am J Hematol. 2023;98(1):11–22. doi: 10.1002/ajh.26741
   PubMed Web of Science ®Google Scholar
• Kanter J, Walters MC, Krishnamurti L, et al. Biologic and clinical efficacy of LentiGlobin for sickle cell disease. N Engl J Med. 2022;386(7):617–628. doi: 10.1056/NEJMoa2117175
   PubMed Web of Science ®Google Scholar
• Spencer Chapman M, Cull AH, Ciuculescu MF, et al. Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease. Nat Med. 2023;29(12):3175–3183. doi: 10.1038/s41591-023-02636-6
   PubMedGoogle Scholar
• Goyal S, Tisdale J, Schmidt M, et al. Acute myeloid leukemia case after gene therapy for sickle cell disease. N Engl J Med. 2022;386(2):138–147. doi: 10.1056/NEJMoa2109167
   PubMed Web of Science ®Google Scholar
• Lubeck D, Agodoa I, Bhakta N, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374. doi: 10.1001/jamanetworkopen.2019.15374
   PubMed Web of Science ®Google Scholar
• Jeste ND, Sánchez LM, Urcuyo GS, et al. Stroke avoidance for children in República Dominicana (SACRED): protocol for a prospective study of stroke risk and hydroxyurea treatment in sickle cell anemia. JMIR Res Protoc. 2017;6(6):e107. doi: 10.2196/resprot.7491
   PubMedGoogle Scholar
• Study details | study of two doses of crizanlizumab versus placebo in adolescent and adult sickle cell disease patients | ClinicalTrials.Gov [Internet]. [cited 2023 Dec 10]. Available from: https://www.clinicaltrials.gov/study/NCT03814746
   Google Scholar
• Andemariam B, Mant T, Eleftheriou P, et al. Treatment with IMR-687, a highly selective PDE9 inhibitor, increases HbF and reduces VOCs in adults with sickle cell disease in a long-term, phase 2a, open-label extension study. Blood. 2021;138(Supplement 1):2046. doi: 10.1182/blood-2021-149536
   Google Scholar
• Lucarelli G, Isgrò A, Sodani P, et al. Hematopoietic SCT for the black African and non-black African variants of sickle cell anemia. Bone Marrow Transplant. 2014;49(11):1376–1381. doi: 10.1038/bmt.2014.167
   PubMed Web of Science ®Google Scholar
• Hsieh MM, Fitzhugh CD, Weitzel RP, et al. Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype. JAMA. 2014;312(1):48–56. doi: 10.1001/jama.2014.7192
   PubMed Web of Science ®Google Scholar
• Ozdogu H, Boga C, Yeral M, et al. Allogenic peripheral stem cell transplantation from HLA-matched related donors for adult sickle cell disease: remarkable outcomes from a single-center trial. Bone Marrow Transplant. 2018;53(7):880–890. doi: 10.1038/s41409-018-0111-y
   PubMed Web of Science ®Google Scholar
• Ozdogu H, Boga C, Yeral M, et al. Excellent outcomes of allogeneic transplantation from peripheral blood of HLA-matched related donors for adult sickle cell disease with ATLG and posttransplant cyclophosphamide-containing regimen: an update work. Bone Marrow Transplant England. 2020;55(8):1647–1651. doi: 10.1038/s41409-020-0805-9
   PubMed Web of Science ®Google Scholar
• Ballas S.K. The evolving pharmacotherapeutic landscape for the treatment of Sickle Cell Disease. Mediterr J Hematol Infect Dis. 2020;12(1):e2020010.
   Google Scholar